Company profile

Medyria AG

Medyria has developed a unique technology for the direct measurement of the Blood Flow Velocity (BFV) and is developing medical devices that integrates the BFV sensor. Recently we started the development of the PyCath, the only microcatheter on the planet earth that allows the full assessment of the heart physiology with a direct blood flow velocity measurement. This has a huge benefit for all patients, because completes the common coronary coronary study with an assessment of the microcirculation, bringing the eligibility of angina pectoris patients from 50% to 100%. Besides this main project Medyria offers its sensing technology though an OEM business model that is successfully leading to the development of new cardiovascular devices functioning on the BFV measurement.

More news about Medyria AG

27.11.2023 17:00

Sparks IPO Academy prepares new cohort for next move

Please login or
register to use the
awards follow feature
24.10.2019 11:10

Four Swiss startups to explore China

Please login or
register to use the
awards follow feature
27.03.2019 09:35

10 Winners of Venture Leaders Life Sciences Selected

Please login or
register to use the
awards follow feature
02.11.2018 13:58

Medyria First in Man Clinical Trial well under way

Please login or
register to use the
awards follow feature
11.06.2015 10:27

Three New CTI Start-up Label Companies

Please login or
register to use the
awards follow feature
30.01.2015 14:05

Medyria AG closes Series A Funding Round of CHF 2.2 million

Please login or
register to use the
awards follow feature
07.03.2014 12:11

Pionierpreis 2014: Die 3 Finalisten stehen fest

Please login or
register to use the
awards follow feature
29.11.2013 14:52

11 companies selected for the next Swiss Venture Day

Please login or
register to use the
awards follow feature
25.10.2013 14:55

CEO Day 2013: a huge and efficient event - updated

Please login or
register to use the
awards follow feature
Medyria AG

Founded
2012

Kanton
ZH

Homepage

rss